ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

IFRX InflaRx NV

1,36
-0,02 (-1,45%)
Zuletzt aktualisiert: 19:22:16
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
InflaRx NV IFRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,02 -1,45% 1,36 19:22:16
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,40 1,28 1,4492 1,38
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202413:30GLOBEInflaRx to Host Virtual R&D Event on June 5, 2024 and..
24.4.202413:30GLOBEInflaRx to Participate in Capital One Securities 1st Annual..
21.3.202412:00GLOBEInflaRx Reports Full Year 2023 Results and Announces INF904..
19.3.202412:30GLOBEInflaRx to Announce Development Plans for INF904 and 2023..
22.2.202413:30GLOBEInflaRx Appoints Jan Medina as Head of Investor Relations
25.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25.1.202413:30GLOBEInflaRx Announces Initiation of its Commitment Program for..
04.1.202422:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.1.202413:00GLOBEInflaRx Announces Positive Topline Results from the Multiple..
06.11.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.11.202313:30GLOBEInflaRx Announces First Patient Dosed in Phase III Trial..
01.11.202313:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.11.202312:30GLOBEInflaRx Reports Third Quarter 2023 Financial Results and..
11.9.202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.9.202313:00GLOBEInflaRx Announces Positive Topline Results from the Single..
30.8.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.8.202313:30GLOBEInflaRx’s Marketing Authorization Application (MAA) for..
10.8.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.8.202313:30GLOBEInflaRx Reports Second Quarter 2023 Financial Results &..
12.7.202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12.7.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30.6.202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
28.6.202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.6.202313:30GLOBEInflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
21.6.202313:00GLOBEInflaRx Announces Commercial Launch of Gohibic (vilobelimab)..
11.5.202313:30GLOBEInflaRx Reports First Quarter 2023 Financial and Operating..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock